Clinical pharmacology of lorazepam.

Contemporary anesthesia practice Pub Date : 1983-01-01
C D Blitt
{"title":"Clinical pharmacology of lorazepam.","authors":"C D Blitt","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>As a preanesthetic medication, lorazepam is available for oral, intravenous, or intramuscular administration. A parenteral dose of 0.04 to 0.06 mg per kg has been shown to be most effective as a preanesthetic medication in terms of antianxiety and antirecall effect (Table 1). Lorazepam has as its predominant advantage over other benzodiazepines the ability to produce anterograde amnesia reliably and for a relatively long duration. From an anesthesia standpoint, the drug finds its major usage as a premedicant or adjuvant (administered in the peri-induction period) to minimize the possibility of recall of unpleasant events during anesthesia and surgery. This is especially germane in patients who are unable to tolerate a sufficient depth of anesthesia to provide this amnesic effect on the basis of anesthetic agent alone. Quite often these patients are critically ill, and from a physiologic standpoint, their cardiovascular systems are unable to tolerate or adapt to moderate to deep anesthetic concentrations of the inhalation anesthetic agents. Even though the metabolic products of lorazepam are not active, the duration of action of this drug dictates that it not be used in the outpatient setting. Indeed, the drug probably should not be used in patients whose expected hospital stay is less than 72 hours. It appears that thrombosis or phlebitis after intravenous injection of lorazepam is less than with diazepam, especially if the drug is injected in small hand or arm veins. Most side effects of lorazepam are associated with central nervous system depression, are dose-related, and fairly predictable. Adverse central nervous system effects may be reversed by administration of physostigmine, but it is worthwhile to note that the duration of action of physostigmine, and repeated administration of physostigmine may be necessary. Lorazepam appears to be acceptable to both physicians and patients. There do not appear to be any obvious adverse interactions between lorazepam and other medications commonly used in anesthesia practice. Nevertheless, it appears that the major value of lorazepam to the anesthesiologist's armamentarium is its ability to prevent recall in appropriate situations.</p>","PeriodicalId":75737,"journal":{"name":"Contemporary anesthesia practice","volume":"7 ","pages":"135-45"},"PeriodicalIF":0.0000,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary anesthesia practice","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

As a preanesthetic medication, lorazepam is available for oral, intravenous, or intramuscular administration. A parenteral dose of 0.04 to 0.06 mg per kg has been shown to be most effective as a preanesthetic medication in terms of antianxiety and antirecall effect (Table 1). Lorazepam has as its predominant advantage over other benzodiazepines the ability to produce anterograde amnesia reliably and for a relatively long duration. From an anesthesia standpoint, the drug finds its major usage as a premedicant or adjuvant (administered in the peri-induction period) to minimize the possibility of recall of unpleasant events during anesthesia and surgery. This is especially germane in patients who are unable to tolerate a sufficient depth of anesthesia to provide this amnesic effect on the basis of anesthetic agent alone. Quite often these patients are critically ill, and from a physiologic standpoint, their cardiovascular systems are unable to tolerate or adapt to moderate to deep anesthetic concentrations of the inhalation anesthetic agents. Even though the metabolic products of lorazepam are not active, the duration of action of this drug dictates that it not be used in the outpatient setting. Indeed, the drug probably should not be used in patients whose expected hospital stay is less than 72 hours. It appears that thrombosis or phlebitis after intravenous injection of lorazepam is less than with diazepam, especially if the drug is injected in small hand or arm veins. Most side effects of lorazepam are associated with central nervous system depression, are dose-related, and fairly predictable. Adverse central nervous system effects may be reversed by administration of physostigmine, but it is worthwhile to note that the duration of action of physostigmine, and repeated administration of physostigmine may be necessary. Lorazepam appears to be acceptable to both physicians and patients. There do not appear to be any obvious adverse interactions between lorazepam and other medications commonly used in anesthesia practice. Nevertheless, it appears that the major value of lorazepam to the anesthesiologist's armamentarium is its ability to prevent recall in appropriate situations.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
劳拉西泮的临床药理学。
作为麻醉前药物,劳拉西泮可用于口服、静脉注射或肌肉注射。在抗焦虑和抗回忆作用方面,0.04 - 0.06 mg / kg的肠外剂量已被证明是最有效的麻醉前用药(表1)。与其他苯二氮卓类药物相比,劳拉西泮的主要优势是能够可靠地产生顺行性遗忘,并且持续时间相对较长。从麻醉的角度来看,该药物的主要用途是作为前药或辅助药(在围诱导期使用),以尽量减少麻醉和手术期间不愉快事件回忆的可能性。这在不能耐受足够深度的麻醉以提供仅基于麻醉剂的健忘症效果的患者中尤为重要。这些患者通常病情危重,从生理学角度来看,他们的心血管系统无法耐受或适应吸入麻醉剂的中度至深度麻醉浓度。尽管劳拉西泮的代谢产物没有活性,但这种药物的作用时间决定了它不能在门诊使用。事实上,这种药物可能不应该用于预期住院时间少于72小时的患者。静脉注射劳拉西泮后血栓或静脉炎的发生率似乎低于地西泮,特别是如果药物注射在手或手臂的小静脉中。劳拉西泮的大多数副作用与中枢神经系统抑郁有关,与剂量有关,而且相当可预测。对中枢神经系统的不良影响可以通过服药来逆转,但值得注意的是,服药的持续时间和反复服药可能是必要的。劳拉西泮似乎对医生和病人都是可以接受的。在麻醉实践中,劳拉西泮与其他常用药物之间似乎没有任何明显的不良相互作用。尽管如此,对于麻醉师来说,劳拉西泮的主要价值似乎是它在适当情况下防止回忆的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Anesthesia and ENT surgery. Anesthesia for combined heart and lung transplantation. Cocaine applications in otorhinolaryngologic anesthesia. Considerations for managing the airway in the ENT patient. Catecholamine anesthetic interaction in ENT surgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1